Levamlodipine

CHEMBL2111097 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
408.9 g/mol
LogP
3.0
Phase
4

This is the pharmacologically active form (S-enantiomer) of amlodipine, a calcium channel blocker used to treat high blood pressure and angina by relaxing blood vessel walls. Using the single active enantiomer may allow for effective treatment at lower doses compared to the racemic mixture.

分子量

408.9000 g/mol

LogP

3.00

TPSA

99.90 Ų

リピンスキーの五則

適合

治療領域

作用機序

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl

InChI

InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1

Molecular Formula

C20H25ClN2O5

HBD / HBA

2 / 7

回転可能結合数

10

重原子数

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This is the pharmacologically active form (S-enantiomer) of amlodipine, a calcium channel blocker used to treat high blood pressure and angina by relaxing blood vessel walls. Using the single active enantiomer may allow for effective treatment at lower doses compared to the racemic mixture.

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Yes, Levamlodipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111097. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9822750. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.